|
US2013129791A1
|
|
Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
|
|
WO2012093977A1
|
|
Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
|
|
WO2012064306A2
|
|
Effervescent formulations of rosuvastatin
|
|
WO2012064307A1
|
|
Pharmaceutical compositions comprising rosuvastatin
|
|
WO2011152810A1
|
|
Formulations comprising calcium, vitamin d and vitamin k for osteoporosis
|
|
WO2011078823A1
|
|
Compositions containing salmeterol, fluticasone and cromoglicic acid
|
|
WO2011053265A2
|
|
The parmaceutical compositions comprising calcium and vitamin d
|
|
WO2011049538A2
|
|
Pharmaceutical composition in dry powder form
|
|
WO2011078818A1
|
|
Dry powder combination of tiotropium, a corticosteroid and a cromoglicic acid derivative
|
|
WO2011078816A1
|
|
Dry powder combination of tiotropium, formoterol and a cromoglicic acid derivative
|
|
WO2011037549A2
|
|
Dry powder formulation of tiotropium carried in blister strip
|
|
WO2011034514A2
|
|
Stable micronized granules having high solubility
|
|
WO2011025467A1
|
|
Solid dosage forms comprising telmisartan
|
|
EP2552911A1
|
|
Tiotropium bromide preparation process
|
|
WO2011002424A2
|
|
Solubility and stability enchancing pharmaceutical formulation comprising ezetimibe and simvastatin
|
|
WO2011002422A2
|
|
Solubility enhancing pharmaceutical formulation
|
|
EP2448575A2
|
|
Pharmaceutical composition increasing solubility and stability
|
|
WO2010101538A2
|
|
New crystalline forms of tiotropium bromide
|
|
WO2010090612A1
|
|
Stable, taste and odor masked pharmaceutical compositions comprising acetylcystein and vitamin c
|
|
WO2010090614A1
|
|
Pharmaceutical formulation comprising risedronate, calcium carbonate and vitamin d3 combined in a single dosage form
|
